Trial
NCT03791918
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sun Yat-sen University
Collaborators
Kaiping Central Hospital; Guangzhou No.12 People's Hospital
Condition
Hepatocellular Carcinoma
Intervention
Lenvatinib
Why stopped
No participants enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-02